The new drug TEV-48125 will be able to relieve Chronic Migraine within 7 days

An experimental drug may bring fast relief to people with debilitating chronic migraines, a new study finds.

Chronic migraine is a distinct and relatively recently defined sub-type of Chronic Daily Headache. The International Headache Society defines chronic migraine as more than fifteen headache days per month over a three month period of which more than eight are migrainous, in the absence of medication over use. Episodic migraine is the other migraine sub-type, which is defined as less than 15 headache days per month.

The World Health Organisation (WHO) has recognised the impact of migraine worldwide and categorised it as the same level of disability as dementia, quadriplegia and acute psychosis. Furthermore WHO classified chronic migraine as more disabling than blindness, paraplegia angina or rheumatoid arthritis.6

Many of the therapies prescribed for chronic migraine are the same as those prescribed for episodic migraine. These include both prescription and over the counter painkillers and as well as migraine specific drugs such as triptans. These are known as abortive or acute medications.

Preliminary trials had already found that the drug -- dubbed TEV-48125 -- can help prevent migraine attacks in people who've suffered long-term with headaches.

Dr. Mark Green is professor of neurology and anesthesiology at the Mount Sinai Icahn School of Medicine, in New York City. "It appears that this antibody works quite quickly," said Green, who is also director of the Center for Headache and Pain Medicine at Mount Sinai.

Green, who was not involved in the study, called the findings "exciting." That's in part because if CGRP-blockers make it to the market, they would be the first drugs specifically designed to prevent migraines.

If TEV-48125 or its competitors are approved, it's unlikely that patients will be put off by having to take a monthly injection, according to Green. "These are people in chronic pain," he pointed out.

But cost could be an obstacle: In general, antibody drugs like TEV-48125 are very expensive. So patients might find it difficult to get insurance coverage, Green said.

Disclaimer: This is a nonprofit blog. My objective, as a young girl born in 1999, is just to share my passion for Medicine by giving the world some information about the latest tendencies in this field. Please click on the links below to obtain a more detailed information about the articles I have used as a source.


http://www.webmd.com/migraines-headaches/news/20160608/experimental-drug-acts-fast-against-chronic-migraine

https://www.migrainetrust.org/about-migraine/types-of-migraine/chronic-migraine/